Live·Open questions in longevity research
All news
Longevity researchTherapeutics

Weight-reducing compounds increased median lifespan in male mice by 6,2 % in the lightest weight quartile and 20,2 % in the heaviest: a preprint attributes most of the difference to early deaths among untreated heavy mice

13 November 2026· 261113008

Weight-reducing compounds increased median lifespan in male mice by 6,2 % in the lightest weight quartile and 20,2 % in the heaviest: a preprint attributes most of the difference to early deaths among untreated heavy mice

On November 11, University College London researchers Paul-Edouard Bouvet and Linda Partridge (founding director of the Max Planck Institute for Biology of Ageing) posted a preprint, a paper that has yet to undergo peer review. They analyzed body weight and lifespan in 33 780 mice from the Interventions Testing Program (ITP). In the ITP, three laboratories test compounds expected to extend lifespan (geroprotectors) in genetically heterogeneous mice, comparing treated mice with controls.

Mice in this US National Institute on Aging program have unrestricted access to food. In 2010, researchers at the institute described many standard laboratory control rodents as “sedentary, obese” and “on a trajectory to premature death.” In 2024, aging researcher Kamil Pabis and colleagues examined lifespan-extension experiments: the shorter the control mice lived, the larger the percentage increase in lifespan. The gains in treated mice therefore have two possible explanations: a compound extends the life of a healthy animal, or it restores some of the lifespan lost to excess weight in heavy mice. Under the first explanation, the gain would be the same at any body weight; under the second, it would increase with body weight.

In 30 ITP experiments with weight-reducing compounds, male mice were weighed at six months of age, before treatment began, so the compounds could not have affected their weight. Within each experiment, males were divided into weight quartiles. Control males in the lightest quartile weighed an average of 34,4 g, compared with 46,9 g in the heaviest. In the lightest quartile, median lifespan was 890 days for controls and 945 days for treated mice; in the heaviest, it was 673 and 809 days, respectively.

From the lightest to the heaviest quartile, median lifespan fell by 217 days in control males and by 136 days in treated males, producing a larger treatment benefit at higher body weights. By day 500, 27,6 % of heavy control males had died, compared with 6,3 % of light control males. Heavy treated males (809 days) lived shorter lives than light control males (890). The authors interpret this pattern as partial protection against the risk associated with body weight, consistent with the second explanation. Weight at 1,4 months of age, during puberty, did not affect the lifespan gain: the weight gained in adulthood mattered.

For compounds that do not reduce weight, lifespan gains did not consistently increase with body weight. For 13 of the 14 weight-reducing compounds, the gain was larger in the heaviest quartile than in the lightest. Rapamycin, acarbose, canagliflozin, and 17α-estradiol affect glucose metabolism and cellular nutrient sensors. Even in the lightest quartile, they extended lifespan by 6–8 %: the authors suggest that these compounds have effects beyond weight loss.

No relationship with body weight was found in females. The authors suggest that this may reflect the low rate of early deaths among ITP control females, leaving little scope for treatment to prevent early mortality. By day 500, 2,4 % of females had died, compared with 16,0 % of males.

Even the lightest quartile (34,4 g) weighed more than comparable males on a restricted diet (around 29 g), which lived an average of 32 % longer than mice with unrestricted access to food. For future experiments, the authors propose comparing the leading compounds with two types of controls: mice with unrestricted access to food and mice given measured portions. The controls in the study of the appetite suppressant semaglutide also had unrestricted access to food: the drug increased median lifespan in old females by 12 %. The authors write in the abstract:

“The geroprotective effects of these interventions may therefore be less pronounced in metabolically healthier mice or humans.”
Originally published on Telegram by Ukhvat NewsView on Telegram
Sources
#interventions-testing-program#body-weight#lifespan#geroprotectors#early-mortality#male-mice